Clinical Trial: Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ine

Brief Summary: This is an open label pilot study of combining BV in a licensed indication with imatinib in patients with ALCL. It is intended as a "window of opportunity" trial in which the study drugs will be given as an initial substitute for conventional chemotherapy with the intention to achieve a remission enabling the patients to proceed to autologous or allogeneic stem cell transplantation, if eligible.